Radhika Walling

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer

Milan Radovich, Guanglong Jiang, Bradley A. Hancock et al. · JAMA Oncology · 2020 · 302 citations · Full text

Medicine, Oncology, Breast Oncology +16

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

Greg Andrew Durm, Salma K. Jabbour, Sandra K. Althouse et al. · Cancer · 2020 · 164 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Matthew D. Galsky, Amir Mortazavi, Matthew I. Milowsky et al. · Journal of Clinical Oncology · 2020 · 133 citations · Full text

Medicine, Oncology, Pharmacology +7

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Bryan P. Schneider, Guanglong Jiang, Tarah J. Ballinger et al. · Journal of Clinical Oncology · 2021 · 53 citations

Medicine, Oncology, Pharmacology +17

Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.

Christopher Hoimes, Nabil Adra, Mark T. Fleming et al. · Journal of Clinical Oncology · 2020 · 50 citations

Medicine, Oncology, Urology +17